By 2050, one in six Saudi residents will be over the age of 65. By 2035, the projected shortfall in inpatient beds reaches 40,000. The two numbers are not separate datapoints. They describe a single structural problem with a single class of solution. The Saudi healthcare system cannot build its way out of the demand curve it is now facing. Hospital beds take five to seven years to plan, finance, build, and commission. The demographic curve is moving faster than the physical infrastructure can. Homecare is the release valve, and the data shows it is already scaling rapidly: home healthcare visits grew 17.4% annually between 2014 and 2018, reaching 955,369 visits in 2018 alone. The Ministry of Health funded over 1.5 million home visits through public programmes by 2020.
The capacity arithmetic is straightforward. Saudi Arabia is currently at approximately 2.2 hospital beds per thousand population, well below the OECD average. The non-communicable disease burden is significant: NCDs account for 73% of all deaths in Saudi Arabia, with diabetes prevalence projected at 11.9% of the adult population in 2025. Chronic disease drives admissions, length of stay, and readmission. Without an alternative care setting capable of absorbing meaningful volume, the system reaches a capacity wall.
Homecare is therefore not a question of whether. The question is whether the governance, regulation, reimbursement, and clinical accountability architecture exists to scale it responsibly. As of 2026, the answer is mostly no.
The Three Operational Models Competing for the Saudi Market
The market is currently served by three distinct operational models, each with different cost structures, clinical capabilities, and governance maturity. The choices made over the next 24 months about which models scale, which are reimbursed, and which are regulated as clinical settings rather than convenience services will determine the structure of Saudi care delivery for the next decade.
The first is the Ministry of Health public homecare programme. The 2024 strategic initiative confirmed 244 home healthcare departments staffed by over 2,700 professionals, delivering chronic care, dialysis, and palliative care under the Health Sector Transformation Programme. This is the largest scale homecare delivery in the country, integrated with the public hospital system, and operating without the friction of insurance reimbursement. Its limit is staffing capacity and geographic coverage, not commercial viability.
The second is the private specialist homecare provider model. Operators including Amana Healthcare, Manzil Healthcare Services, and similar entities deliver complex homecare including ventilation, IV therapy, post-acute rehabilitation, and palliative care. Their reimbursement environment is mixed: some services covered by major insurers under specific protocols, others paid out of pocket, others packaged into corporate or premium insurance products. The clinical capability is high. The governance maturity varies.
The third is the hospital-extension model: tertiary providers offering home discharge programmes, hospital-at-home services, and post-acute monitoring as an extension of inpatient care. This model is the most clinically integrated but the least financially mature. Most hospitals offering home extension services are absorbing the cost as a length-of-stay reduction strategy, with reimbursement following inpatient logic rather than separate homecare logic.
The structural choice in front of the Saudi system is not whether to scale homecare. The data has already settled that question. The choice is whether the regulatory, reimbursement, and clinical governance frameworks evolve fast enough to ensure the scaling produces the cost containment and outcome improvement the system needs, rather than simply replicating fee-for-service inefficiency in a different setting.
The AR-DRG Catalyst
The transition from fee-for-service to AR-DRG bundled episode payments changes the economic logic of homecare in a way that few have fully internalised. Under fee-for-service, every additional inpatient day is a revenue line. Under DRG, every additional inpatient day after the optimal length of stay is a cost line. The hospital that discharges a clinically appropriate patient to homecare on day four of a five-day DRG episode captures the same reimbursement as the hospital that holds the patient until day five and absorbs the additional cost.
This single mechanism shifts homecare from a cost centre to a margin lever. Hospitals operating in a DRG environment have a direct financial incentive to discharge appropriate patients earlier, with structured home support that reduces readmission risk and protects the episode reimbursement. The same incentive applies to the homecare provider receiving the discharge: they are now part of an integrated care episode, not a separate billable service.
For payers, the calculation is parallel. A homecare episode that prevents an admission, reduces length of stay, or prevents a 30-day readmission is a margin-positive intervention. The PMPM cost of structured homecare for high-risk chronic disease cohorts is consistently lower than the cost of acute utilisation those cohorts would otherwise generate. The data exists in NPHIES to identify those cohorts. The contracts to capture the savings are not yet widely in place.
The Governance Architecture That Does Not Yet Exist
A homecare programme operating at the scale Saudi Arabia now needs requires an institutional architecture that has not yet been built in most organisations. Five components are conspicuously absent in the current market.
The first is reimbursement model design. Saudi insurers have not yet standardised how homecare is paid: whether per visit, per episode, per bundled chronic disease month, or as part of an integrated DRG episode reimbursement. Each model creates different incentives, different cost dynamics, and different fraud risks. The absence of a standardised model means homecare is contracted bilaterally between payers and providers without sector-level governance.
The second is clinical accreditation and oversight. Homecare delivers genuinely clinical services in a non-clinical environment. The home is not a hospital. The professional licensing, infection control, medication administration, and medical equipment standards that apply in hospital settings have analogues in homecare, but those analogues are incompletely defined and inconsistently enforced. The clinical risk of large-scale homecare delivery without parallel clinical governance is material.
The third is workforce planning. The 244 MoH departments and 2,700 professionals are the visible portion. The market also requires private sector capacity scaling at a similar rate, in a labour environment where Saudi qualified nursing capacity is constrained and expatriate labour is being progressively localised. The workforce required to support the scale-up does not currently exist in country.
The fourth is technology infrastructure. Remote monitoring, telehealth integration, electronic visit verification, medication adherence support, and care coordination platforms are all required for homecare to operate as a managed clinical service rather than a series of isolated visits. NPHIES does not currently extend natively into the homecare service environment.
The fifth is integration with the broader care system. A homecare episode that does not connect to the patient hospital record, the patient pharmacy record, the patient primary care provider, and the payer claims system operates as a parallel system. The integration is technically possible. It is not yet operationally standard.
Strategic questions on homecare
- What proportion of the current admission and readmission rate is theoretically diverible to structured homecare?
- What is the PMPM cost differential between structured chronic disease homecare and the acute utilisation it prevents?
- Which homecare provider relationships are scalable, accredited, and integrated with NPHIES claims and clinical data?
- How does AR-DRG bundling change the case for prepayment vs fee-for-service homecare reimbursement?
Strategic questions on homecare
- Is hospital-at-home a margin-positive extension under AR-DRG, or a cost-shifting that erodes the episode reimbursement?
- What clinical pathways have been redesigned to discharge to home rather than extending inpatient length of stay?
- Does homecare expansion fit within the existing licence, or does it require a separate clinical governance framework?
- How is readmission risk managed in the post-discharge home environment, and who is clinically accountable?
Why the Window Is Now
The combination of factors making the next 24 months consequential for homecare governance is unusual. The AR-DRG transition reaches operational scale through 2026 and 2027. The NISS expansion to 23 million beneficiaries adds population to a system where bed capacity is fixed in the short term. The Insurance Authority RBC framework requires payers to ground their actuarial assumptions in actual claims data, including the cost dynamics of alternative care settings. The CHI essential benefit package is being reviewed in the context of these changes. The investment cycle for new private homecare operators is active, with international entrants assessing the Saudi market.
The organisations that build their homecare governance architecture in this window will operate with structural advantages through the next reform cycle: established provider relationships, integrated reimbursement models, validated clinical pathways, and analytical evidence of cost and outcome impact. The organisations that defer the question will find the market structured around them rather than by them.
Homecare is no longer optional. The decisions about how it is structured remain.